Earnings Call Summary | Mirion(MIR.US) Q1 2024 Earnings Conference
Earnings Call Summary | Mirion(MIR.US) Q1 2024 Earnings Conference
The following is a summary of the Mirion Technologies, Inc. (MIR) Q1 2024 Earnings Call Transcript:
以下是 Mirion Technologies, Inc. (MIR) 2024 年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Mirion Technologies reported a Q1 2024 organic revenue growth of 5.5%, in line with expectations.
Their technologies business displayed the most growth with an 8% increase.
Adjusted EBITDA rose by 8% year-over-year, reaching nearly $40 million for the quarter.
A 40 basis point expansion in adjusted EBITDA margin was primarily due to the contributions of the technologies business.
The company reaffirmed its 2024 financial forecasts, anticipating 4% to 6% organic revenue growth and an adjusted EBITDA between $193 million and $203 million.
Despite a negative cash flow in Q1, due to a strategic investment, the company remains confident in adhering to guidance and targets positive cash flow in H1.
Mirion lowered its inventory by $11 million year-over-year, with future improvements anticipated.
Mirion Technologies報告稱，2024年第一季度有機收入增長5.5％，符合預期。
他們的技術業務增長最快，增長了8％。
調整後的息稅折舊攤銷前利潤同比增長8％，本季度達到近4000萬美元。
調整後的息稅折舊攤銷前利潤率增長了40個點子，這主要歸因於技術業務的貢獻。
該公司重申了其2024年的財務預測，預計有機收入增長4％至6％，調整後的息稅折舊攤銷前利潤將在1.93億美元至2.03億美元之間。
儘管由於戰略投資，第一季度現金流爲負數，但該公司仍然有信心遵守指導方針，並計劃在上半年實現正現金流。
Mirion的庫存同比減少了1100萬美元，預計未來將有所改善。
Business Progress:
業務進展：
With healthy end markets, driven by enhancements in nuclear power and cancer care, Mirion is expecting consistent top-line growth.
The company commercialized its InstadoseVUE technology, beginning with a soft launch in Q1 2024.
To achieve its 5-year target of a 30% adjusted EBITDA margin, the company is advancing its French business and continues to invest in digital capabilities, AI, and new product development.
The company foresees growth opportunities in the globally expanding sectors of nuclear power and cancer care, with the latter already representing nearly 30% of the company's total revenue.
The company is targeting long-term strategic partnerships in the rapidly growing nuclear industry.
The acquisition of the EC squared software platform is expected to boost order growth for nuclear medicine.
Mirion expects a 'material' growth in orders for Small Modular Reactors (SMRs).
Recovery from earlier ERP integration issues in Europe is being noted, with strong performance seen in March and April.
Growth is projected in Department of Energy-funded life sciences lab activities, planning to leverage their excellent gamma spectroscopy capabilities to improve efficiency and safety in the nuclear medicine sector.
在覈電和癌症醫療改善的推動下，終端市場保持健康，Mirion預計收入將持續增長。
該公司將其InstadoSevue技術商業化，首先是2024年第一季度的試推出。
爲了實現調整後息稅折舊攤銷前利潤率達到30％的5年目標，該公司正在推進其法國業務，並繼續投資於數字能力、人工智能和新產品開發。
該公司預見了全球擴張的核電和癌症護理領域的增長機會，後者已經佔公司總收入的近30％。
該公司的目標是在快速增長的核工業中建立長期戰略合作伙伴關係。
收購EC Squared軟件平台有望促進核醫學的訂單增長。
Mirion預計，小型模塊化反應堆（SMR）的訂單將出現 “實質性” 增長。
歐洲早些時候的ERP整合問題已經恢復過來，3月和4月表現強勁。
能源部資助的生命科學實驗室活動預計將增長，計劃利用其卓越的伽瑪光譜能力來提高核醫學領域的效率和安全性。
More details: Mirion IR
更多詳情： Mirion IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。